产品资料

Anti-OPG (P25) Antibody

如果您对该产品感兴趣的话,可以
产品名称: Anti-OPG (P25) Antibody
产品型号:
产品展商: 其它品牌
产品文档: 无相关文档

简单介绍

Anti-OPG (P25) Antibody


Anti-OPG (P25) Antibody  的详细介绍
Name: Anti-OPG (P25) Antibody
See all OPG primary antibodies
Description: Rabbit polyclonal antibody to OPG (P25)
Specificity: OPG (P25) pAb detects endogenous levels of Osteoprotegerin protein.
Applications: WB, IHC, IF
Reactivity: Human, Mouse, Rat
Immunogen: Synthetic peptide, corresponding to amino acids 1-50 of Human OPG.
Host: Rabbit
Clonality: Polyclonal
Conjugate: Unconjugated
Molecular Weight: ~ 46 kDa
Purity: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Product Form: 1 mg/ml in Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.2.
Function: Acts as decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis.
Tissue Specificity: Highly expressed in ***** lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
Involvement in Disease: Paget disease of bone 5, juvenile-onset: An autosomal recessive, juvenile-onset form of Paget disease, a disorder of bone remodeling characterized by increased bone turnover affecting one or more sites throughout the skeleton, primarily the axial skeleton. Osteoclastic overactivity followed by compensatory osteoblastic activity leads to a structurally disorganized mosaic of bone (woven bone), which is mechanically weaker, larger, less compact, more vascular, and more susceptible to fracture than normal ***** lamellar bone. PDB5 clinical manifestations include short stature, progressive long bone deformities, fractures, vertebral collapse, skull enlargement, and hyperostosis with progressive deafness.
Post-Translational Modification: N-glycosylated. Contains sialic acid residues.
Cellular Location: Secreted.
Database Links:
  • Entrez Gene: 4982?Human
  • Entrez Gene: 18383?Mouse
  • Entrez Gene: 25341?Rat
  • Omim: 602643?Human
  • SwissProt: O00300?Human
  • SwissProt: O08712?Mouse
  • SwissProt: O08727?Rat
  • Unigene: 81791?Human
  • Unigene: 15383?Mouse
  • Unigene: 202973?Rat
    		•
    Synonyms:
  • MGC29565 Antibody
  • MGC93568 Antibody
  • OCIF Antibody
  • OPG Antibody
  • Osteoclastogenesis inhibitory factor Antibody
  • Osteoprotegerin Antibody
  • PDB5 Antibody
  • TNF receptor superfamily member 11b Antibody
  • TNFRSF 11B Antibody
  • TNFRSF11B Antibody
  • TR 1 Antibody
  • TR1 Antibody
  • TR11B_HUMAN Antibody
  • Tumor necrosis factor receptor superfamily member 11B Antibody
    		•
    Information: Target information shown above is from the UniProt Consortium.
    产品留言
    标题
    联系人
    联系电话
    内容
    验证码
    点击换一张
    注：1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
    2.如有必要,请您留下您的详细联系方式!

    沪公网安备 31011202007337号